Tamoxifen

"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Descriptor ID	D013629
MeSH Number(s)	D02.455.426.559.389.150.700.900
Concept/Terms	Tamoxifen Tamoxifen ICI-47699 ICI-47699 ICI 47699 ICI47699 Nolvadex Nolvadex Novaldex Tamoxifen Citrate Tamoxifen Citrate Citrate, Tamoxifen Tomaxithen Tomaxithen Zitazonium Zitazonium ICI-46474 ICI-46474 ICI 46474 ICI46474 ICI-46,474 ICI 46,474 ICI46,474 Soltamox Soltamox

Below are MeSH descriptors whose meaning is more general than "Tamoxifen".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Benzylidene Compounds [D02.455.426.559.389.150]
Stilbenes [D02.455.426.559.389.150.700]
Tamoxifen [D02.455.426.559.389.150.700.900]

Below are MeSH descriptors whose meaning is related to "Tamoxifen".

Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.

Bar chart showing 46 publications over 20 distinct years, with a maximum of 4 publications in 2015 and 2016 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
2003	2	0	2
2005	1	1	2
2006	1	1	2
2007	1	1	2
2008	1	0	1
2009	1	1	2
2010	0	3	3
2011	2	1	3
2012	1	2	3
2013	2	0	2
2014	1	0	1
2015	2	2	4
2016	2	2	4
2017	3	0	3
2018	1	3	4
2019	1	1	2
2020	2	0	2
2022	0	1	1
2025	1	1	2

Below are the most recent publications written about "Tamoxifen" by people in Profiles.

Digman A, Pajarillo E, Kim S, Ajayi I, Son DS, Aschner M, Lee E. Tamoxifen induces protection against manganese toxicity by REST upregulation via the ER-a/Wnt/?-catenin pathway in neuronal cells. J Biol Chem. 2025 06; 301(6):108529.

View in: PubMed
Rault L, Raidoo S. Therapeutic Options for Unscheduled Bleeding on Hormonal Contraception. Obstet Gynecol Clin North Am. 2025 Jun; 52(2):331-346.

View in: PubMed
Umbarkar P, Tousif S, Singh AP, Anderson JC, Zhang Q, Tallquist MD, Woodgett J, Lal H. Fibroblast GSK-3a Promotes Fibrosis via RAF-MEK-ERK Pathway in the Injured Heart. Circ Res. 2022 09 16; 131(7):620-636.

View in: PubMed
Robinson AGJ, Kanaan YM, Copeland RL. Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines. Anticancer Res. 2020 Dec; 40(12):6623-6635.

View in: PubMed
Edelman AB, Kaneshiro B, Simmons KB, Hauschildt JL, Bond K, Boniface ER, Jensen JT. Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: A Randomized Controlled Trial. Obstet Gynecol. 2020 08; 136(2):323-332.

View in: PubMed
Wang Z, Katsaros D, Biglia N, Shen Y, Loo L, Yu X, Lin H, Fu Y, Chu WM, Fei P, Ni Y, Jia W, Deng X, Qian B, Yu H. ERa upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-?B in breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):353-368.

View in: PubMed
Korecki AJ, Hickmott JW, Lam SL, Dreolini L, Mathelier A, Baker O, Kuehne C, Bonaguro RJ, Smith J, Tan CV, Zhou M, Goldowitz D, Deussing JM, Stewart AF, Wasserman WW, Holt RA, Simpson EM. Twenty-Seven Tamoxifen-Inducible iCre-Driver Mouse Strains for Eye and Brain, Including Seventeen Carrying a New Inducible-First Constitutive-Ready Allele. Genetics. 2019 04; 211(4):1155-1177.

View in: PubMed
Chowdhury N, Vhora I, Patel K, Bagde A, Kutlehria S, Singh M. Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. AAPS PharmSciTech. 2018 Oct; 19(7):3287-3297.

View in: PubMed
Campbell PS, Mavingire N, Khan S, Rowland LK, Wooten JV, Opoku-Agyeman A, Guevara A, Soto U, Cavalli F, Loaiza-P?rez AI, Nagaraj G, Denham LJ, Adeoye O, Jenkins BD, Davis MB, Schiff R, Brantley EJ. AhR ligand aminoflavone suppresses a6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells. J Cell Physiol. 2018 01; 234(1):108-121.

View in: PubMed
Kumar BNP, Puvvada N, Rajput S, Sarkar S, Mahto MK, Yallapu MM, Pathak A, Emdad L, Das SK, Reis RL, Kundu SC, Fisher PB, Mandal M. Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. Mol Pharm. 2018 07 02; 15(7):2698-2713.

View in: PubMed

People

Explore

Similar Concepts

Top Journals